title: Academic-industrial collaboration in the development of the first angiotensin receptor blocker: neprilysin inhibitor in the treatment of heart failure.
authors.affiliation: From the TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital, Department of Medicine, Harvard Medical School, 350 Longwood Avenue, 1st office floor, Boston, MA 02115, USA ebraunwald@partners.org.
authors.forename: Eugene
authors.initials: E
authors.lastname: Braunwald
mesh_terms: D000613:Aminobutyrates / Q000627:therapeutic use*; D057911:Angiotensin Receptor Antagonists / Q000627:therapeutic use*; D001713:Biphenyl Compounds; D000072096:Cardiologists; D017277:Drug Approval; D004338:Drug Combinations; D055808:Drug Discovery; D004345:Drug Industry; D006333:Heart Failure / Q000188:drug therapy*; D006801:Humans; D007400:Interprofessional Relations; D015260:Neprilysin / Q000037:antagonists & inhibitors; D013777:Tetrazoles / Q000627:therapeutic use*; D000068756:Valsartan
chemical_list: D000613:Aminobutyrates; D057911:Angiotensin Receptor Antagonists; D001713:Biphenyl Compounds; D004338:Drug Combinations; D013777:Tetrazoles; D000068756:Valsartan; D015260:Neprilysin; C549068:sacubitril and valsartan sodium hydrate drug combination